Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Essential Thrombocythemia · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm
Megakaryocytic Neoplasm
Essential Thrombocythemia

Hematologic Malignancy

Essential Thrombocythemia

CI-CAN-00002631ETExplore in graph →

Hematologic24 active trials1 approved drugs2 evidence items

NCIt: C3407
OncoTree: ET
DOID: 2224
UMLS CUI: C0040028

Overview
Statistics
Survival
Genomics
Variants & evidence2
Drugs1
Trials93
Research
Rankings
Sources & provenance

MeSH

Data completeness4 / 7 dimensions

Epidemiology (no data yet)
Survival (no data yet)
Trials (data present)
Literature (data present)
Genomics (no data yet)
Evidence (data present)
Therapies (data present)

Computed from entity_counters.completeness · refreshed after each connector run

Definition

What this entity is

A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)

Definition text as published by ncit-evsProvenance

Source: NCI Thesaurus (NCIt)
Dataset: NCI Thesaurus
Version: 26.08e
Retrieved: Sep 8, 2026
Layer: raw (as published)
Evidence: expert curation
License: CC BY 4.0
Run: ING-NCITEVS-20260908-000001

Open at source Curated

Data updated 22 days agoSource updated 26.08e

Taxonomy

Position in the hierarchies

Several hierarchies coexist; edges are listed per hierarchy type with their source.

Parents

ncit

Megakaryocytic NeoplasmHematologic Malignancy
Myeloproliferative Neoplasm, BCR-ABL1 NegativeMolecular Subtype

oncotree

Myeloproliferative NeoplasmHematologic Malignancy

Children (4)

ncit

Essential Thrombocythemia with CALR Mutation
Essential Thrombocythemia with JAK2 Mutation
Essential Thrombocythemia with MPL Mutation

oncotree

Essential Thrombocythemia Myelofibrosis

Anatomy

Anatomical sites

Hematopoietic and Lymphatic SystemC35813

Record

Identity

CancerIndex ID: CI-CAN-00002631
Entity type: Hematologic Malignancy
Malignant: Yes
Solid / hematologic: Hematologic
Pediatric relevant: Not flagged
Rare cancer: Unknown (no incidence data yet)
Hierarchy depth: 5
Classification version: 26.08e
Semantic types: Neoplastic Process
Status: Active
Record updated: 2026-09-08

Coverage

Data completeness

Trials (all / active)

93 / 24

Publications (all / 5y)

3,689 / 548

Evidence items

2

Genes / variants

1 / 2

Drugs (any / approved)

1 / 1

Genomic cohorts

0

Epidemiology / survival obs.

0 / 0

Data updated 42 minutes agoSource updated unknowncounters aggregate over descendants

Names

Synonyms (14)

Thrombocythemia, Essentialmesh_heading · MeSH
Essential (hemorrhagic) thrombocythemiasynonym · NCIt
Essential Thrombocytemiasynonym · NCIt
Essential Thrombocythemiasynonym · OncoTree
Essential Thrombocythemiassynonym · MeSH
Essential Thrombocytosissynonym · NCIt
Hemorrhagic Thrombocythemiasynonym · MeSH
Hemorrhagic Thrombocythemiassynonym · MeSH
Idiopathic Thrombocythemiasynonym · NCIt
Idiopathic Thrombocythemiassynonym · MeSH
Primary Thrombocythemiasynonym · NCIt
Primary Thrombocythemiassynonym · MeSH
Primary Thrombocytosessynonym · MeSH
Primary Thrombocytosissynonym · NCIt

CancerIndex is a research and information platform. It does not diagnose and does not recommend treatment.

Key figures

At a glance

Each figure carries its unit, period and source; ranks link to "Why this rank?".

No registry-level ancestor: burden figures are published for the mutually exclusive top-level site groups only, and this entity does not descend from one. Global figures (IARC / GLOBOCAN) stay under license review and SEER awaits credentials.

Active trials24countcurrent registry status · entity + descendantsclinicaltrialsComputedrank #412 of 1,654 (World · both sexes · all ages · latest · all malignant entities)
Recruiting trials15countstatus RECRUITING · entity + descendantsclinicaltrialsComputedrank #370 of 1,284 (World · both sexes · all ages · latest · all malignant entities)
Curated evidence items2countaccepted CIViC items · entity + descendantscivicComputedrank #342 of 492 (World · both sexes · all ages · latest · all malignant entities)
Publications, last 12 months65countPubMed records · stored query · 12-month windowpubmedComputedrank #403 of 2,294 (World · both sexes · all ages · latest · all malignant entities)
Genomic cohorts0countopen GDC projects · entity + descendantsgdcComputednot in a current ranking snapshot

Data updated 42 minutes agoSource updated unknownregistry figures: none · counters aggregate over descendants